News & Events

Investors

E-mail Alerts

Apr 7, 2021

Viking Therapeutics to Present at 20th Annual Needham Virtual Healthcare Conference

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...
Mar 4, 2021

Viking Therapeutics to Participate at Upcoming Investor Conferences

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...
Feb 17, 2021

Viking Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update

Conference call scheduled for 4:30 p.m. ET today

Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...
Feb 10, 2021

Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2020 on February 17, 2021

Conference Call Scheduled for Wednesday, February 17 at 4:30 p.m. Eastern Time

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today...
Jan 6, 2021

Viking Therapeutics Announces Senior Management Team Appointments

Greg Zante Promoted to Chief Financial Officer and Marianne Mancini Promoted to Chief Operating Officer

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...